Option chain shows key data for Pasithea Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Pasithea Therapeutics.

Pasithea Therapeutics (NASDAQ:KTTA) Stock, Option Chain

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

Crude Oil

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRTO

KTTA

VLCN

Crude Oil Down 2%; ISM Services PMI Falls In January

The Walt Disney Co.

LTRY

OGEN

US Stocks Mixed; Walt Disney Posts Upbeat Earnings

Prague,cz,-27,April,2023:,Logo,On,Accenture,Headquarters,In,Prague.

CNXC

MDXH

RYDE

TBIO

Dow Surges Over 250 Points; Accenture Earnings Top Views

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Press Releases

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Health Care

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

General

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Technical Explosions: DUO, KTTA, TBIO, GOTU – Watch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum!

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

GOTU

KTTAW

PNPNF

PRSO

TSXV:PNPN

TSXV:YGT

YGTFF

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Apollomics

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

NuCana

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Vincerx Pharma

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

EF Hutton

Comments

Pasithea Therapeutics

Pasithea Therapeutics (KTTA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga